Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|January 18, 2024
Novartis Acquires Calypso Biotech for up to $425 Million
Author(s)Daria G. Husni
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
Advertisement
On Jan. 8, 2024, Calypso Biotech, a European immunotherapy biotech company focused on the research and development of novel biologics, announced it had agreed to be acquired by Novartis. Calypso’s shareholders are set to receive an upfront payment of $250 million and are eligible to receive development milestones of up to $175 million, based on reaching certain milestones.
Calypso, a spin-out from Merck, is engaged in the research and development of monoclonal antibodies for a range of autoimmune indications, with a specialization in IL-15 biology. IL-15, according to Calypso, is a broad, untapped immune axis that controls barrier function and downstream immune cascades in many chronic autoimmune diseases. Calypso’s lead product candidate. CALY-002 is a potential best-in-class therapeutics antibody that binds to and neutralizes Interleukin-15.
This acquisition will give Novartis full rights to CALY-002, which it intends to explore further across a wide range of autoimmune indications with unmet medical need. CALY-002 is currently in a Phase Ib trial in patients with celiac disease and eosinophilic esophagitis.
“We are excited for this transaction with Novartis, a company with relentless commitment to the development of innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively, so that it can promptly address unmet medical needs in multiple indications,” said Alain Vicari, chief executive officer and co-founder of Calypso.
Bernard Coulie, chairman, Calypso, added, “The transaction with Novartis constitutes the high point in the development path of CALY-002 for the Calypso team. Calypso has established a significantly de-risked profile for CALY-002 as a potential best-in-class therapeutic anti-IL-15 antibody.”
“Novartis is committed to bringing innovative treatment options forward for patients living with immunological diseases,” said Richard Siegel, head of Immunology Research at Novartis in a Calypso press release. “We’re thrilled to add Calypso’s potential best-in-class antibody to our Immunology pipeline and explore it in a spectrum of autoimmune indications.”
Source:
Advertisement
Related to this article
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement